Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis.
OBJECTIVE
To evaluate the efficacy and safety of treatment with recombinant growth hormone (rGH) in patients with cystic fibrosis (CF).


METHODS
Twenty patients with CF (aged 10-23 years) were randomised to age and sex matched treatment and control groups. The treatment group received daily subcutaneous injections of 1 IU/kg/wk rGH for 12 months. Pulmonary function (forced expiratory volume in one second (FEV1) and airway resistance), exercise capacity measured with a bicycle ergometer, body composition (dual energy x ray absorptiometry), and weight were assessed at the beginning of the study and after 6 and 12 months.


RESULTS
rGH treatment did not improve weight and pulmonary function, but lean body mass increased significantly in the treatment group. Exercise capacity increased in the treatment group from 143 (16) W (mean (SD)) to 164 (19) W after 12 months of rGH treatment.


CONCLUSIONS
Treatment of CF patients with rGH for one year improved the exercise capacity significantly but not pulmonary function. The improved exercise capacity needs confirmation in a larger population before such an expensive treatment is justified.
Schibler
A
A
Paediatric Respiratory Medicine, Department of Paediatrics, University of Bern, CH-3010 Bern, Switzerland. andreas_schibler@mater.org.au
von der Heiden
R
R
Birrer
P
P
Mullis
P E
PE
D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy*; D017079:Exercise Tolerance; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000502:physiology; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010101:Oxygen Consumption / Q000502:physiology; D011446:Prospective Studies; D019141:Respiratory System Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D014797:Vital Capacity / Q000502:physiology
D019141:Respiratory System Agents; D013006:Growth Hormone